Patents by Inventor Zehra Visram

Zehra Visram has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230220055
    Abstract: The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae, which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.
    Type: Application
    Filed: August 16, 2022
    Publication date: July 13, 2023
    Applicant: X4 PHARMACEUTICALS (AUSTRIA) GMBH
    Inventors: Valeria SZIJARTO, Gábor NAGY, Luis GUACHALLA, Zehra VISRAM, Eszter NAGY, Jolanta Katarzyna LUKASIEWICZ
  • Patent number: 11466074
    Abstract: The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae, which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: October 11, 2022
    Assignee: X4 PHARMACEUTICALS (AUSTRIA) GMBH
    Inventors: Valeria Szijarto, Gábor Nagy, Luis Guachalla, Zehra Visram, Eszter Nagy, Jolanta Katarzyna Lukasiewicz
  • Publication number: 20180298084
    Abstract: A human or humanized monoclonal IgG antibody (mAb) specifically recognizing the D-galactan-II antigen of Klebsiella pneumoniae O1 which is characterized by a bactericidal CDC activity, its method of production, medical and diagnostic use.
    Type: Application
    Filed: October 14, 2016
    Publication date: October 18, 2018
    Applicant: ARSANIS BIOSCIENCES GMBH
    Inventors: Eszter NAGY, Gábor NAGY, Valeria SZIJÁRTO, Luis Miguel GUACHALLA, Irina MIRKINA, Zehra VISRAM
  • Publication number: 20180179267
    Abstract: An anti-Staphylococcus aureus antibody combination preparation comprising a) a toxin cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (HIa) and at least one of the bi-component toxins selected from the group consisting of HIg AB, HIg CB, LukSF, LukED, Luk S-HIg B, LukSD, HIg A-LukD, HIg A-LukF, Luk EF, LukE-HIg B, HIg C-LukD and HIg C-LukF; and b) an anti-Luk GH antibody; and/or c) an OPK antibody which recognizes a S. aureus surface protein thereby inducing OPK, specifically an anti-Ig-binding protein (IGBP) antibody comprising at least one CDR binding site recognizing any of the S. aureus Ig G binding domains of Protein A or Sbi.
    Type: Application
    Filed: April 14, 2016
    Publication date: June 28, 2018
    Inventors: Eszter NAGY, Adriana BADARAU, Harald ROUHA, Lukas STULIK, Zehra VISRAM
  • Patent number: 9914767
    Abstract: The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of Staphylococcus aureus, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated conformational epitope recognized by a specific cross-neutralizing antibody.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: March 13, 2018
    Assignee: ARSANIS BIOSCIENCES GMBH
    Inventors: Eszter Nagy, Adriana Badarau, Harald Rouha, Lukas Stulik, Gábor Nagy, Irina Mirkina, Zoltán Magyarics, Zehra Visram, Michaela Jaegerhofer, Manuel Zerbs, Ivana Dolezilkova, Astrid Teubenbacher, Michael Benjamin Battles, Bianka Dominique Prinz
  • Publication number: 20180066041
    Abstract: The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae , which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.
    Type: Application
    Filed: November 3, 2015
    Publication date: March 8, 2018
    Inventors: Valeria SZIJÁRTO, Gábor NAGY, Luis GUACHALLA, Zehra VISRAM, Eszter NAGY, Jolanta Katarzyna LUKASIEWICZ
  • Publication number: 20150086539
    Abstract: The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of Staphylococcus aureus, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated conformational epitope recognized by a specific cross-neutralizing antibody.
    Type: Application
    Filed: April 17, 2013
    Publication date: March 26, 2015
    Inventors: Eszter Nagy, Adriana Badarau, Harald Rouha, Lukas Stulik, Gábor Nagy, Irina Mirkina, Zoltán Magyarics, Zehra Visram, Michaela Jaegerhofer, Manuel Zerbs, Ivana Dolezilkova, Astrid Teubenbacher, Michael Benjamin Battles, Bianka Dominique Prinz